Erytech Pharma: Jumps on U.S. FDA's fast track tag for pancreatic cancer therapy

Phaxiam Therapeutics SA

29/04/2020 17:02

** U.S.-listed shares of France-based biotech company
 ERYP.O  jump 18% to $10.33 
    ** U.S. FDA grants fast track designation to company's
investigational drug to treat pancreatic cancer
    ** Co's lead candidate, eryaspase, is in late-stage trial
and is being evaluated in 11 countries, including U.S.
    ** An interim analysis is expected around year-end and the
final analysis in the second half of 2021
    ** Up to Tuesday's close, stock had risen ~40% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((mailto:dania.nadeem@thomsonreuters.com))